KR20180096558A - Antiviral Composition Comprising a Carrageenan as an Active Ingredient - Google Patents
Antiviral Composition Comprising a Carrageenan as an Active Ingredient Download PDFInfo
- Publication number
- KR20180096558A KR20180096558A KR1020180096704A KR20180096704A KR20180096558A KR 20180096558 A KR20180096558 A KR 20180096558A KR 1020180096704 A KR1020180096704 A KR 1020180096704A KR 20180096704 A KR20180096704 A KR 20180096704A KR 20180096558 A KR20180096558 A KR 20180096558A
- Authority
- KR
- South Korea
- Prior art keywords
- carrageenan
- composition
- virus
- lambda
- influenza
- Prior art date
Links
- 239000000679 carrageenan Substances 0.000 title claims abstract description 74
- 229920001525 carrageenan Polymers 0.000 title claims abstract description 74
- 229940113118 carrageenan Drugs 0.000 title claims abstract description 74
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 239000004480 active ingredient Substances 0.000 title claims abstract description 10
- 235000010418 carrageenan Nutrition 0.000 title abstract description 27
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 title abstract description 26
- 230000000840 anti-viral effect Effects 0.000 title abstract description 22
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 150000004676 glycans Chemical class 0.000 claims abstract description 27
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 27
- 239000005017 polysaccharide Substances 0.000 claims abstract description 27
- 201000010099 disease Diseases 0.000 claims abstract description 26
- 241000709661 Enterovirus Species 0.000 claims abstract description 20
- 208000015181 infectious disease Diseases 0.000 claims abstract description 12
- 206010057190 Respiratory tract infections Diseases 0.000 claims abstract description 5
- 235000013376 functional food Nutrition 0.000 claims abstract description 5
- 230000009385 viral infection Effects 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 208000035473 Communicable disease Diseases 0.000 claims description 12
- 241000197306 H1N1 subtype Species 0.000 claims description 12
- 241000252870 H3N2 subtype Species 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 241000710203 Human rhinovirus 1B Species 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 241000713196 Influenza B virus Species 0.000 claims description 3
- 206010006448 Bronchiolitis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010011416 Croup infectious Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 201000007100 Pharyngitis Diseases 0.000 claims description 2
- 206010061494 Rhinovirus infection Diseases 0.000 claims description 2
- 208000024716 acute asthma Diseases 0.000 claims description 2
- 208000021240 acute bronchiolitis Diseases 0.000 claims description 2
- 208000016150 acute pharyngitis Diseases 0.000 claims description 2
- 206010001093 acute tonsillitis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000010549 croup Diseases 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 201000008197 Laryngitis Diseases 0.000 claims 1
- 206010044302 Tracheitis Diseases 0.000 claims 1
- 201000010550 acute laryngitis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 49
- 238000011282 treatment Methods 0.000 abstract description 9
- 239000000427 antigen Substances 0.000 abstract description 4
- 230000027645 antigenic variation Effects 0.000 abstract description 4
- 102000036639 antigens Human genes 0.000 abstract description 4
- 108091007433 antigens Proteins 0.000 abstract description 4
- 229960005486 vaccine Drugs 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 239000005445 natural material Substances 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 36
- 230000000694 effects Effects 0.000 description 25
- 238000012360 testing method Methods 0.000 description 17
- 206010022000 influenza Diseases 0.000 description 15
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 13
- 229940072056 alginate Drugs 0.000 description 13
- 235000010443 alginic acid Nutrition 0.000 description 13
- 229920000615 alginic acid Polymers 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 208000037798 influenza B Diseases 0.000 description 11
- 238000000134 MTT assay Methods 0.000 description 9
- 231100000002 MTT assay Toxicity 0.000 description 9
- 239000008121 dextrose Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 6
- 229920001661 Chitosan Polymers 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229920002674 hyaluronan Polymers 0.000 description 6
- 229960003160 hyaluronic acid Drugs 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 208000037797 influenza A Diseases 0.000 description 5
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 5
- 229940061367 tamiflu Drugs 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical class O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000312 effect on influenza Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000037799 influenza C Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- -1 lambda-carrageenan Chemical class 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/731—Carrageenans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/502—Gums
- A23V2250/5036—Carrageenan
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 카라기난을 유효성분으로 포함하는 항-바이러스 조성물에 관한 것이다.The present invention relates to an anti-viral composition comprising carrageenan as an active ingredient.
카라기난(carrageenan)은 해초(red edible seaweeds)에서 추출되는 천연 중합체로서, 갈락토오스(galactose)를 단량체로 하는 고분자 폴리사카라이드이다. 카라기난은 유화제(emulsifier), 증점제(thickener), 겔화제(gelling agent) 및 안정화제(stabilizer) 등으로 이용되어온 약품/식품 첨가물로서, γ-, β-, δ-, α-, μ-, κ-, λ-, ι- 및 ν-형의 아형을 가진다. 이 중 3가지 주요 아형은 이오타(ι, iota)-, 카파(κ, kappa)- 및 람다(λ, lambda)-카라기난으로, 이들은 갈락토오스 단량체의 결합구조와 황산화(sulphatation) 위치가 상이하다. Carrageenan is a natural polymer extracted from red edible seaweeds and is a high molecular polysaccharide containing galactose as a monomer. Carrageenan is a drug / food additive that has been used as an emulsifier, thickener, gelling agent, and stabilizer. It has been widely used as γ-, β-, δ-, α-, μ-, -,? -, ι- and ν-type subtypes. Three major subtypes are iota (ι, iota) -, kappa (κ, kappa) - and lambda (λ, lambda) - carrageenan which differ in the binding structure and sulphatation position of galactose monomers.
코감기바이러스로도 불리우는 리노바이러스(rhinovirus)는 최소한 100개의 혈청형(serotype)으로 구성되고, 일반 감기의 일차적인 원인균(causative agent)으로 알려졌다. 다수의 혈청형이 존재하여 백신의 개발이 어려우며, 가장 합리적인 치료적 접근으로서 항-바이러스제(antiviral agent)가 고려되고 있다. 리노바이러스는 4개의 바이러스 단백질인 VP1, VP2, VP3과 VP4를 보유하는 주위 캡시드(surrounding capsid)로 구성되며, 이 중 VP1, VP2 및 VP3은 60개의 반복 프로타메릭 이코사헤드랄 단위(repeating protameric icosahedral unit)로 이루어져 이들이 리노바이러스의 항원 다양성(antigen diversity)의 원인이 되는 것으로 생각된다. Rhinovirus, also known as the nosebleed virus, is composed of at least 100 serotypes and is known as the causative agent of the common cold. Many serotypes are present, making it difficult to develop vaccines, and antiviral agents are considered as the most reasonable therapeutic approach. The virus consists of four viral proteins, VP1, VP2, VP3 and surrounding capsids carrying VP4, of which VP1, VP2 and VP3 contain 60 repetitive protameric units icosahedral unit), which is thought to be responsible for the antigen diversity of the rhinovirus.
인플루엔자 바이러스는 단일쇄 RNA 바이러스인 오르토믹소 바이러스(orthomyxovirus)로서, 인플루엔자 A, B, 및 C로 나누어진다. 이 중 인플루엔자 A와 B 바이러스는 유행성 인간 질환의 원인이 되는 두 가지 타입의 인플루엔자 바이러스이며, 이들은 일반적으로 사람간의 접촉, 주로 호흡기 비말(droplet) 전파를 통하여 퍼진다. 인플루엔자 A 및 인플루엔자 B의 H1N1 및 H3N2 서브타입이 계절 감염병의 주요한 원인이 되는 것으로 알려져 있다. 인플루엔자 바이러스는 표면 HA(haemagglutinin)와 NA(neuraminidase)의 아미노산의 변화로 인한 항원성 변이를 통해 체액성 면역시스템을 회피할 수 있다. 이러한 이유로 인해, 인플루엔자는 지속적인 백신 개발에도 불구하고 매년 유행병을 일으킬 수 있다. 대부분의 환자는 의학적 처치를 받지 않고서도 인플루엔자에 의한 열병과 증상으로부터 회복되지만, 인플루엔자 바이러스 감염으로 인한 증상이 심한 경우 사망에까지도 이를 수 있다.Influenza viruses are orthomyxoviruses, a single-stranded RNA virus, which are divided into influenza A, B, and C. Among them, influenza A and B viruses are two types of influenza viruses that cause pandemic human disease, and they are generally spread through human contact, mainly through respiratory droplet propagation. The H1N1 and H3N2 subtypes of influenza A and influenza B are known to be the major causes of seasonal infections. Influenza viruses can avoid the humoral immune system through antigenic variation caused by changes in the amino acids of surface HA (haemagglutinin) and NA (neuraminidase). For this reason, influenza can cause an epidemic every year despite continued vaccine development. Most patients recover from fever and symptoms due to influenza without medical treatment, but even death from severe influenza virus infection can occur.
이에, 항원 다양성 또는 항원성 변이 등을 이유로 백신을 통한 치료를 담보할 수 없는 이들 바이러스 관련 질환에 있어, 효율적이고 부작용 없는 항-바이러스제 개발의 요구가 커지고 있다. Therefore, there is a growing demand for the development of efficient and non-adverse anti-viral agents for these virus-related diseases, which can not be cured by vaccination due to antigen diversity or antigenic variation.
본 명세서 전체에 걸쳐 다수의 논문 및 특허문헌이 참조되고 그 인용이 표시되어 있다. 인용된 논문 및 특허문헌의 개시 내용은 그 전체로서 본 명세서에 참조로 삽입되어 본 발명이 속하는 기술 분야의 수준 및 본 발명의 내용이 보다 명확하게 설명된다.Numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated herein by reference in their entirety to better understand the state of the art to which the present invention pertains and the content of the present invention.
본 발명자들은 급성 호흡기 감염증의 대표적인 원인 바이러스인 리노바이러스 또는 인플루엔자 바이러스에 대한 효율적인 치료 조성물을 개발하고자 예의 연구 노력하였다. 그 결과, 천연물 유래 다당체인 람다-카라기난, 카파-카라기난 및 이오타-카라기난으로 구성된 군으로부터 선택되는 황산화 다당류가 낮은 독성을 가지면서도 이들 바이러스에 대한 높은 항-바이러스 활성을 가진다는 사실을 발견함으로써, 본 발명을 완성하게 되었다.The present inventors have made extensive efforts to develop an effective therapeutic composition for a rhinovirus or influenza virus, which is a typical causative virus of acute respiratory infections. As a result, it has been found that sulfated polysaccharides selected from natural product-derived polysaccharides lambda-carrageenan, kappa-carrageenan and iota-carrageenan have low toxicity and high antiviral activity against these viruses, Thereby completing the present invention.
따라서 본 발명의 목적은 리노바이러스(rhinovirus) 또는 인플루엔자 바이러스(influenza virus) 감염 질환의 예방 또는 치료용 조성물을 제공하는 데 있다.Accordingly, an object of the present invention is to provide a composition for preventing or treating rhinovirus or influenza virus infectious diseases.
본 발명의 다른 목적은 리노바이러스 또는 인플루엔자 바이러스 감염 질환의 개선 또는 완화용 기능성 식품 조성물을 제공하는 데 있다.Another object of the present invention is to provide a functional food composition for improving or alleviating a disease caused by infection with a rhinovirus or influenza virus.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명, 청구범위 및 도면에 의해 보다 명확하게 된다.Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.
본 발명의 일 양태에 따르면, 본 발명은 람다(Lambda)-카라기난(carrageenan), 카파(Kappa)-카라기난 및 이오타(Iota)-카라기난으로 구성된 군으로부터 선택되는 황산화 다당류(sulfated polysaccharides) 또는 이의 약제학적으로 허용 가능한 염을 유효성분으로 포함하는 리노바이러스(rhinovirus) 또는 인플루엔자 바이러스(influenza virus) 감염 질환의 예방 또는 치료용 조성물을 제공한다. According to one aspect of the invention, the present invention relates to sulfated polysaccharides selected from the group consisting of Lambda-carrageenan, Kappa-carrageenan and Iota-carrageenan, The present invention provides a composition for preventing or treating rhinovirus or influenza virus infectious diseases, which comprises a pharmaceutically acceptable salt as an active ingredient.
본 발명자들은 급성 호흡기 감염증의 대표적인 원인 바이러스인 리노바이러스 또는 인플루엔자 바이러스에 대한 효율적인 치료 조성물을 개발하고자 예의 연구 노력하였다. 그 결과, 천연물 유래 다당체인 람다-카라기난, 카파-카라기난 및 이오타-카라기난으로 구성된 군으로부터 선택되는 황산화 다당류가 낮은 독성을 가지면서도 이들 바이러스에 대한 높은 항-바이러스 활성을 가진다는 사실을 발견하였다. The present inventors have made extensive efforts to develop an effective therapeutic composition for a rhinovirus or influenza virus, which is a typical causative virus of acute respiratory infections. As a result, it has been found that sulfated polysaccharides selected from natural product-derived polysaccharides such as lambda-carrageenan, kappa-carrageenan and iota-carrageenan have low toxicity and high antiviral activity against these viruses.
본 발명에 따르면, 이들 황산화 다당류는 리노바이러스 또는 인플루엔자 바이러스에 감염된 세포의 생존률을 크게 향상시킴과 동시에 낮은 세포독성을 보임으로써 안전하고 효율적인 항-바이러스 조성물로 유용하게 이용될 수 있음이 확인되었다. According to the present invention, it has been confirmed that these sulfated polysaccharides can be usefully used as a safe and effective anti-viral composition by greatly improving the survival rate of cells infected with a rhinovirus or influenza virus and exhibiting low cytotoxicity.
본 명세서에서 용어“항-바이러스 활성”은 바이러스 감염 주기, 구체적으로는 숙주세포에의 바이러스 침투(virus penetration), 바이러스 복제(virus replication), 바이러스 조합(virus assembly) 및 바이러스 방출(virus release)로 이루어진 바이러스 감염 주기의 하나 이상의 단계를 직접 또는 간접적으로 간섭 또는 억제하는 활성을 의미한다. 이는 바이러스 감염 개체 내에서의 바이러스 역가 증가(virus titer increase)를 불특정하게 저해하거나, 또는 바이러스 역가 수준(virus titer level)을 불특정하게 감소시키는 임의의 효과를 모두 포함한다. As used herein, the term " anti-viral activity " refers to a period of viral infection, specifically virus penetration into host cells, viral replication, virus assembly and virus release Quot; means an activity that directly or indirectly interferes or inhibits one or more steps of the virus infection cycle. This includes any effects that either nonspecifically inhibit the virus titer increase in the viral infected subject, or reduce the virus titer level to nonspecifically.
본 명세서에서 용어“리노바이러스 감염 질환”또는“인플루엔자 바이러스 감염 질환”은 리노바이러스 또는 인플루엔자 바이러스의 감염을 직접 또는 간접적인 원인으로 하여 발생, 진행 또는 악화되는 모든 질환 또는 병적 상태(pathologic condition)을 의미한다.As used herein, the term " renovirus infectious disease " or " influenza virus infectious disease " refers to any disease or pathologic condition that occurs, progresses or worsens due to a direct or indirect cause of infection of a rhinovirus or influenza virus do.
본 명세서에서 용어“치료”는 (a)질환, 질병 또는 증상의 발전의 억제; (b)질환, 질병 또는 증상의 경감; 또는 (c)질환, 질병 또는 증상을 제거하는 것을 의미한다. 본 발명의 조성물은 리노바이러스 또는 인플루엔자 바이러스에 감염된 세포의 생존률을 향상시켜 바이러스 감염에 의한 효과를 억제함으로써 바이러스 감염을 원인으로 하는 질환 또는 이의 증상의 발전을 억제하거나, 이를 제거하거나 또는 경감시키는 역할을 한다. 따라서, 본 발명의 조성물은 그 자체로 리노바이러스 또는 인플루엔자 바이러스 감염 질환의 치료 조성물이 될 수도 있고, 혹은 다른 항-바이러스 조성물과 함께 투여되어 바이러스 활성을 억제하는 치료 보조제로 적용될 수도 있다. 이에, 본 명세서에서 용어“치료”또는“치료제”는“치료 보조”또는“치료 보조제”의 의미를 포함한다. As used herein, the term " treatment " includes (a) inhibiting the development of a disease, disorder or condition; (b) relief of the disease, disorder or condition; Or (c) eliminating the disease, disease or condition. The composition of the present invention has a role of suppressing, eliminating, or alleviating the development of a disease caused by a virus infection or symptoms thereof by improving the survival rate of a cell infected with a lynovirus or influenza virus and suppressing the effect of the virus infection do. Thus, the composition of the present invention may itself be a therapeutic composition for a lynovirus or influenza virus infection disease, or may be applied as a therapeutic adjuvant to be administered with other anti-viral composition to inhibit viral activity. Herein, the term " treatment " or " therapeutic agent " includes the meaning of " therapeutic aid "
본 명세서에서, 용어“예방”은 질환 또는 질병을 보유하고 있다고 진단된 적은 없으나, 이러한 질환 또는 질병에 걸릴 가능성이 있는 대상체에서 질환 또는 질병의 발생을 억제하는 것을 의미한다. As used herein, the term " prophylactic " means inhibiting the development of a disease or disease in a subject who has never been diagnosed as having a disease or disease, but is likely to suffer from such disease or disease.
본 명세서에서 용어“투여”또는“투여하다”는 본 발명의 조성물의 치료적 유효량을 대상체에 직접적으로 투여함으로써 대상체의 체내에서 동일한 양 또는 그에 상응하는 양이 형성되도록 하는 것을 말한다.The term " administering " or " administering " as used herein refers to the administration of a therapeutically effective amount of a composition of the present invention directly to a subject so that the same amount or a corresponding amount is formed in the body of the subject.
조성물의“치료적 유효량”은 조성물을 투여하고자 하는 개체에게 치료적 또는 예방적 효과를 제공하기에 충분한 카라기난의 함량을 의미하며, 이에 “예방적 유효량”을 포함하는 의미이다.A " therapeutically effective amount " of a composition means an amount of carrageenan sufficient to provide a therapeutic or prophylactic effect to the individual to whom the composition is to be administered, including a " prophylactically effective amount ".
본 명세서에서 용어“대상체”는 제한없이 인간, 마우스, 래트, 기니아 피그, 개, 고양이, 말, 소, 돼지, 원숭이, 침팬지, 비비 또는 붉은털 원숭이를 포함한다. 구체적으로는, 본 발명의 대상체는 인간이다. As used herein, the term " subject " includes without limitation humans, mice, rats, guinea pigs, dogs, cats, horses, cows, pigs, monkeys, chimpanzees, baboons or rhesus monkeys. Specifically, the object of the present invention is human.
본 발명의 구체적인 구현예에 따르면, 상기 리노바이러스는 HRV1B(Human rhinovirus 1B)이다.According to a specific embodiment of the present invention, the renovirus is HRV1B (Human rhinovirus 1B).
본 발명의 구체적인 구현예에 따르면, 상기 인플루엔자 바이러스는 인플루엔자 A 바이러스 또는 인플루엔지 B 바이러스이다. 보다 구체적으로, 상기 인플루엔자 A 바이러스는 H1N1 바이러스 또는 H3N2 바이러스이다. According to a specific embodiment of the present invention, the influenza virus is an influenza A virus or an influenza B virus. More specifically, the influenza A virus is H1N1 virus or H3N2 virus.
본 발명의 구체적인 구현예에 따르면, 본 발명에서 이용되는 황산화 다당류는 람다(Lambda)-카라기난(carrageenan)이다. According to a specific embodiment of the present invention, the sulfated polysaccharide used in the present invention is Lambda-carrageenan.
본 발명에서 이용되는 황산화 다당류인 람다-, 카파- 및 이오타-카라기난은 카라기난의 가장 대표적인 3가지 형태로서, 이들은 모두 리노바이러스 및 인플루엔자 A 바이러스에 대해 유의한 항-바이러스 활성을 보인다. 본 발명에 따르면, 이들 중 람다-카라기난은 모든 바이러스 타입에 대한 가장 우수한 항-바이러스 활성을 나타냄이 확인되었다. The sulfated polysaccharides used in the present invention, lambda-, kappa- and iota-carrageenan, are the three most representative forms of carrageenan, all of which exhibit significant anti-viral activity against both linovirus and influenza A virus. According to the present invention, it has been confirmed that lambda-carrageenan has the best antiviral activity for all types of viruses.
본 발명의 구체적인 구현예에 따르면, 본 발명의 람다-카라기난은 100~750 mPa·s의 점도를 가지며, 보다 구체적으로는 200~650 mPa·s의 점도를 가지고, 가장 구체적으로는 250-600 mPa·s의 점도를 가진다. 람다-카라기난의 점도가 100 mPa·s 미만일 경우 비강내 점착성이 떨어져 목표로 하는 효과를 얻을 수 없으며, 람다-카라기난의 점도가 750 mPa·s를 초과할 경우 점도가 높아 용기로부터 분무가 어렵다. According to a specific embodiment of the present invention, the lambda-carrageenan of the present invention has a viscosity of 100 to 750 mPa · s, more specifically 200 to 650 mPa · s, most specifically 250-600 mPa · Has a viscosity of s. When the viscosity of lambda-carrageenan is less than 100 mPa · s, the nasal adhesion deteriorates and the desired effect can not be obtained. When the viscosity of lambda-carrageenan exceeds 750 mPa · s, the viscosity is high and spraying from the container is difficult.
본 발명의 구체적인 구현예에 따르면, 본 발명의 조성물로 치료되는 리노바이러스 감염 질환은 리노바이러스 감염을 원인으로 하는 감기, 폐렴, 기관지염, 천식, 만성폐쇄성 폐질환 및 낭포성 섬유증으로 구성된 군으로부터 선택된다.According to a specific embodiment of the present invention, the rhinovirus infection disease treated with the composition of the present invention is selected from the group consisting of colds, pneumonia, bronchitis, asthma, chronic obstructive pulmonary disease and cystic fibrosis due to a lynovirus infection .
본 발명의 구체적인 구현예에 따르면, 본 발명의 조성물로 치료되는 인플루엔자 바이러스 감염 질환은 인플루엔자 바이러스 감염을 원인으로 하는 기관지염, 비염, 부비동염, 크룹(croup), 급성 세기관지염, 인두염, 편도염, 후두염, 기관염, 천식 및 폐렴으로 구성된 군으로부터 선택된다.According to a specific embodiment of the present invention, the influenza viral infectious disease treated with the composition of the present invention may be used for the treatment of influenza virus infection including bronchitis, rhinitis, sinusitis, croup, acute bronchiolitis, pharyngitis, tonsillitis, Asthma, and pneumonia.
본 발명의 화합물은 약제학적으로 허용 가능한 염의 형태로 사용될 수 있으며, 염으로는 약학적으로 허용 가능한 유리산(free acid)에 의해 형성된 산부가염이 유용하다. 유리산으로는 무기산과 유기산을 사용할 수 있다. The compound of the present invention can be used in the form of a pharmaceutically acceptable salt, and as the salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. As the free acid, inorganic acid and organic acid can be used.
바람직하게는, 본 발명의 화합물의 약제학적 허용 가능한 염은 염산염, 브롬산염, 황산염, 인산염, 구연산염, 아세트산염, 트리플루오로아세트산염, 젖산염, 주석산염, 말레인산염, 푸마르산염, 글루콘산염, 메탄설폰산염, 글리콘산염, 숙신산염, 4-톨루엔설폰산염, 글루쿠론산염, 엠본산염, 글루탐산염, 또는 아스파트산염으로 구성된 군으로부터 선택될 수 있으나, 이에 제한되지 않고 당업계에서 통상적으로 사용되는 다양한 무기산 및 유기산을 이용하여 형성되는 염이 모두 포함된다. 또한, 본 발명의 화합물은 용매화물(예를 들면 수화물)의 형태로도 존재할 수 있다. Preferably, the pharmaceutically acceptable salts of the compounds of the present invention include the hydrochloride, bromate, sulfate, phosphate, citrate, acetate, trifluoroacetate, lactate, tartrate, maleate, fumarate, But are not limited to, sulfonic acid salts, glycolic acid salts, succinic acid salts, 4-toluenesulfonic acid salts, glucuronic acid salts, embronic acid salts, glutamic acid salts or aspartic acid salts, And salts formed using various inorganic acids and organic acids. The compounds of the present invention may also exist in the form of solvates (e.g., hydrates).
본 발명의 조성물은 본 발명의 황산화 다당류의 약제학적 유효량이 포함된 약제학적 조성물로 제조될 수 있다. 본 명세서에서 용어 “약제학적 유효량”은 상술한 본 발명의 리노바이러스 또는 인플루엔자 바이러스 감염 질환의 예방, 경감 또는 치료 효능 또는 활성을 달성하는 데 충분한 양을 의미한다.The composition of the present invention may be prepared from a pharmaceutical composition comprising a pharmaceutically effective amount of the sulfated polysaccharide of the present invention. As used herein, the term " pharmaceutically effective amount " means an amount sufficient to achieve the preventive, palliative, or therapeutic efficacy or activity of the above-described rhinovirus or influenza virus infection disease of the present invention.
본 발명의 약제학적 조성물에 포함되는 약제학적으로 허용되는 담체는 제제시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산칼슘, 알기네이트, 젤라틴, 규산칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약제학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. 적합한 약제학적으로 허용되는 담체 및 제제는 Remington's Pharmaceutical Sciences (19th ed., 1995)에 상세히 기재되어 있다.The pharmaceutically acceptable carriers to be contained in the pharmaceutical composition of the present invention are those conventionally used in the present invention and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약제학적 조성물은 경구 또는 비경구로 투여할 수 있다. 비경구 투여인 경우에는 정맥내 주입, 피하 주입, 근육 주입, 복강 주입, 국소 투여, 경피 투여, 비강 투여 등으로 투여할 수 있다. 가장 바람직하게는 비강 투여(nasal administration)로 투여 된다. The pharmaceutical composition of the present invention can be administered orally or parenterally. In the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, muscle injection, intraperitoneal injection, topical administration, transdermal administration, nasal administration and the like. Most preferably in a nasal administration.
본 발명의 약제학적 조성물의 적합한 투여량은 제제화 방법, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. 한편, 본 발명의 약제학적 조성물이 비강 투여용 조성물로 이용될 경우 바람직한 1회 단위 분무량은 20~500 μg이며, 가장 바람직한 단위 분무량은 50~200 μg이다. 20 μg 미만의 단위 분무량에서는 조성물의 양이 적어 목표로 하는 효과를 얻기가 어려우며, 500 μg 초과의 단위 분무량은 비강내 분무시 조성물이 비강에서 흘러내려 투여에 어려움이 있다.A suitable dosage of the pharmaceutical composition of the present invention can be variously prescribed by such factors as the formulation method, the age, body weight, sex, pathological condition, food, administration time, route of administration, excretion rate and responsiveness of the patient . Meanwhile, when the pharmaceutical composition of the present invention is used as a composition for nasal administration, the preferred unit dose amount is 20 to 500 μg, and the most preferred unit dose amount is 50 to 200 μg. It is difficult to obtain the desired effect with a small amount of the composition at a unit spray amount of less than 20 μg, and a unit spray amount of more than 500 μg causes difficulty in administration because the composition is sprayed from the nasal cavity during nasal spray.
본 발명의 약제학적 조성물은 당해 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조될 수 있다. The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. .
본 발명의 다른 양태에 따르면, 본 발명은 람다(Lambda)-카라기난(carrageenan), 카파(Kappa)-카라기난 및 이오타(Iota)-카라기난으로 구성된 군으로부터 선택되는 황산화 다당류(sulfated polysaccharides)를 유효성분으로 포함하는 리노바이러스(rhinovirus) 또는 인플루엔자 바이러스(influenza virus) 감염 질환의 개선 또는 완화용 기능성 식품 조성물을 제공한다. In accordance with another aspect of the present invention, the present invention provides a method of treating sulfated polysaccharides selected from the group consisting of Lambda-carrageenan, Kappa-carrageenan and Iota-carrageenan, A functional food composition for improving or alleviating a rhinovirus or influenza virus infection disease.
본 발명에서 이용되는 유효성분인 황산화 다당류 및 이를 통해 개선 또는 완화될 수 있는 바이러스 감염 질환에 대해서는 이미 상술하였으므로, 과도한 중복을 피하기 위하여 그 기재를 생략한다.The sulfated polysaccharide as an active ingredient used in the present invention and the viral infectious diseases which can be ameliorated or alleviated through the polysaccharide have already been described above, so that description thereof is omitted in order to avoid excessive redundancy.
본 발명의 조성물이 식품 조성물로 제조되는 경우, 유효성분으로서 본 발명의 황산화 다당류 뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 단당류, 예를 들어, 포도당, 과당 등; 이당류, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 다당류, 예를 들어 덱스트린, 사이클로덱스트 린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스 파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 본 발명의 유효성분인 본 발명의 황산화 다당류 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액 또는 감초 추출액 등을 추가로 포함시킬 수 있다.When the composition of the present invention is prepared as a food composition, it contains not only the sulfated polysaccharide of the present invention as an active ingredient but also a component ordinarily added at the time of food production, for example, protein, carbohydrate, fat, And flavoring agents. Examples of the above-mentioned carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings. For example, in the case where the food composition of the present invention is prepared as a drink, it is possible to use the citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract or licorice extract And the like.
본 발명의 또 다른 양태에 따르면, 본 발명은 다음의 단계를 포함하는 리노바이러스(rhinovirus) 또는 인플루엔자 바이러스(influenza virus) 감염 질환의 예방 또는 치료용 조성물의 제조방법을 제공한다:According to yet another aspect of the present invention, the present invention provides a method for the preparation of a composition for the prevention or treatment of rhinovirus or influenza virus infectious diseases comprising the steps of:
1) 약학적으로 허용되는 담체 및 람다(Lambda)-카라기난(carrageenan), 카파(Kappa)-카라기난 및 이오타(Iota)-카라기난으로 구성된 군으로부터 선택되는 황산화 다당류(sulfated polysaccharides) 또는 이의 약제학적으로 허용 가능한 염을 정제수에 녹이는 단계; 및1) sulfated polysaccharides selected from the group consisting of pharmaceutically acceptable carriers and Lambda-carrageenan, Kappa-carrageenan and Iota-carrageenan, or pharmacologically acceptable salts thereof, Dissolving an acceptable salt in purified water; And
2) 상기 단계 1)에서 얻어진 용액을 무균필터를 포함하는 용기(receptacle)에 충전하는 단계.2) charging the solution obtained in step 1) into a receptacle containing sterile filter.
본 발명의 또 다른 양태에 따르면, 본 발명은 다음의 단계를 포함하는 리노바이러스(rhinovirus) 또는 인플루엔자 바이러스(influenza virus) 감염 질환의 예방 또는 치료용 조성물의 제조방법을 제공한다:According to yet another aspect of the present invention, the present invention provides a method for the preparation of a composition for the prevention or treatment of rhinovirus or influenza virus infectious diseases comprising the steps of:
1) 약학적으로 허용되는 보존제를 정제수에 녹이는 단계: 및1) dissolving a pharmaceutically acceptable preservative in purified water: and
2) 상기 단계 1)에서 얻어진 용액에 약학적으로 허용되는 담체 및 람다(Lambda)-카라기난(carrageenan), 카파(Kappa)-카라기난 및 이오타(Iota)-카라기난으로 구성된 군으로부터 선택되는 황산화 다당류(sulfated polysaccharides) 또는 이의 약제학적으로 허용 가능한 염을 추가적으로 녹이는 단계; 및2) a solution of the sulfated polysaccharide selected from the group consisting of Lambda-carrageenan, Kappa-carrageenan and Iota-carrageenan in a solution which is pharmaceutically acceptable in the solution obtained in step 1) sulfated polysaccharides or a pharmaceutically acceptable salt thereof; And
3) 상기 단계 2)에서 얻어진 용액을 무균필터가 장착 또는 비장착된 용기(receptacle)에 충전하는 단계.3) filling the solution obtained in step 2) into a receptacle with or without an aseptic filter.
본 발명에서 이용되는 유효성분인 황산화 다당류 및 이를 통해 예방 또는 치료될 수 있는 바이러스 감염 질환에 대해서는 이미 상술하였으므로, 과도한 중복을 피하기 위하여 그 기재를 생략한다.The sulfated polysaccharide, which is an active ingredient used in the present invention, and the viral infectious diseases that can be prevented or treated therewith have already been described above, so that description thereof is omitted in order to avoid excessive redundancy.
본 명세서에서 용어“보존제”는 본 발명의 조성물 내에서의 미생물의 증식을 억제하는 항-바이러스 및/또는 항진균 작용을 하는 물질을 의미하며, 예를 들어 파라옥시벤조산, 벤조산, 소르빈산 및 이들의 염을 포함하나 이에 제한되지 않고 당업계에서 사용되는 모든 통상적인 보존제가 사용될 수 있다. As used herein, the term " preservative " means an anti-viral and / or antifungal agent which inhibits the growth of microorganisms in the composition of the present invention. Examples of the preservative include paraoxybenzoic acid, benzoic acid, sorbic acid, But not limited to, any conventional preservative used in the art may be used.
본 명세서에서 용어“정제수(purified water)”는 여과(이온교환), 전자입자탈지 및 증류 등의 과정을 통해 무기물 및 유기물이 제거된 물을 의미하며, 증류수(distilled water)와 동일한 의미로 사용된다. The term " purified water " used herein means water in which inorganic and organic materials have been removed through a process such as filtration (ion exchange), electron particle degreasing and distillation, and is used with the same meaning as distilled water .
본 명세서에서 용어“무균필터(sterile filter)”는 흡착 및/또는 크기 배제(size exclusion)를 통해 여과 작용을 하는 무균화된 여과기를 의미하며, 무균화 방법은 특별한 제한없이 당업계에 통상적으로 알려진 모든 방법이 사용될 수 있다. As used herein, the term " sterile filter " means a sterilized filter that performs filtration through adsorption and / or size exclusion, and the sterilization process may be carried out without particular limitation, All methods can be used.
본 발명의 특징 및 이점을 요약하면 다음과 같다:The features and advantages of the present invention are summarized as follows:
(a) 본 발명은 리노바이러스 또는 인플루엔자 바이러스 감염 질환의 예방 또는 치료용 조성물 및 이들 질환의 개선 또는 완화용 기능성 식품 조성물을 제공한다.(a) The present invention provides a composition for the prophylaxis or treatment of a renovirus or influenza virus infectious disease, and a functional food composition for improving or alleviating these diseases.
(b) 본 발명은 천연물 유래 다당체인 카라기난을 유효성분으로 이용함으로써 독성이 거의 없으며, 호흡기 감염증의 대표적인 원인 바이러스인 리노바이러스 및 인플루엔자 바이러스에 대한 우수한 항-바이러스 활성을 나타낸다.(b) The present invention uses carrageenan, which is a polysaccharide derived from a natural product, as an active ingredient, and shows excellent anti-viral activity against viruses and influenza viruses which are typical causative viruses of respiratory infections.
(c) 본 발명은 항원 다양성 또는 항원성 변이로 인해 백신을 이용한 치료에 한계를 가지는 바이러스 관련 질환에 있어, 효율적이고 부작용 없는 항-바이러스 조성물로 유용하게 이용될 수 있다. (c) The present invention can be effectively used as an efficient and adverse-effect antiviral composition in a virus-related disease having a limitation in treatment with a vaccine due to antigen diversity or antigenic variation.
도 1은 바이러스-유도 CPE(cytopathic effect, CPE) 저해법 및 MTT 분석을 이용하여 카라기난류의 항-리노바이러스 효과를 측정한 결과를 나타내는 그림이다.
도 2는 바이러스-유도 CPE 저해법 및 MTT 분석을 이용하여 프로필렌글리콜(PG) 알기네이트, Na 알기네이트, 교차결합 히알루론산(CLHA) 및 수용성 키토산의 항-리노바이러스 효과를 측정한 결과를 나타내는 그림이다.
도 3은 바이러스-유도 CPE 저해법 및 MTT 분석을 이용하여 카라기난류의 H1N1 타입에 대한 항-인플루엔자 바이러스 효과를 측정한 결과를 나타내는 그림이다.
도 4는 바이러스-유도 CPE 저해법 및 MTT 분석을 이용하여 카라기난류의 H3N2 타입에 대한 항-인플루엔자 바이러스 효과를 측정한 결과를 나타내는 그림이다.
도 5는 바이러스-유도 CPE 저해법 및 MTT 분석을 이용하여 카라기난류의 인플루엔자B 타입에 대한 항-인플루엔자 바이러스 효과를 측정한 결과를 나타내는 그림이다.
도 6은 바이러스-유도 CPE 저해법 및 MTT 분석을 이용하여 프로필렌글리콜(PG) 알기네이트, Na 알기네이트, 교차결합 히알루론산(CLHA) 및 수용성 키토산의 H1N1 타입에 대한 항-인플루엔자 바이러스 효과를 측정한 결과를 나타내는 그림이다.
도 7은 바이러스-유도 CPE 저해법 및 MTT 분석을 이용하여 프로필렌글리콜(PG) 알기네이트, Na 알기네이트, 교차결합 히알루론산(CLHA) 및 수용성 키토산의 H3N2 타입에 대한 항-인플루엔자 바이러스 효과를 측정한 결과를 나타내는 그림이다.
도 8은 바이러스-유도 CPE 저해법 및 MTT 분석을 이용하여 프로필렌글리콜(PG) 알기네이트, Na 알기네이트, 교차결합 히알루론산(CLHA) 및 수용성 키토산의 인플루엔자B 타입에 대한 항-인플루엔자 바이러스 효과를 측정한 결과를 나타내는 그림이다.
도 9는 흰마우스에 인플루엔자 바이러스와 동시에 3% 덱스트로스, 타미플루, 람다-카라기난 및 이오타-카라기난을 각각 1일 2회씩 비강 접종 한 후 체중 변화율을 나타낸 그림이다.
도 10은 흰마우스에 인플루엔자 바이러스와 동시에 3% 덱스트로스, 타미플루, 람다-카라기난 및 이오타-카라기난을 각각 1일 2회씩 비강 접종 한 후 생존율을 나타낸 그림이다.FIG. 1 is a graph showing the results of measurement of the anti-renovirus effect of carrageenan using virus-induced CPE (cytopathic effect, CPE) and MTT assay.
Figure 2 shows the results of measuring anti-renovirus effects of propylene glycol (PG) alginate, Na alginate, cross-linked hyaluronic acid (CLHA) and water-soluble chitosan using virus-induced CPE degradation and MTT assay to be.
FIG. 3 is a graph showing the results of measurement of the anti-influenza virus effect on the H1N1 type of carrageenan using the virus-induced CPE reduction method and the MTT assay.
4 is a graph showing the results of measuring the anti-influenza virus effect on the H3N2 type of carrageenan using the virus-induced CPE reduction method and the MTT assay.
5 is a graph showing the results of measurement of anti-influenza virus effect on influenza B type of carrageenan using virus-induced CPE reduction method and MTT assay.
Figure 6 shows the effect of anti-influenza virus on the H1N1 type of propylene glycol (PG) alginate, Na alginate, cross-linked hyaluronic acid (CLHA) and water-soluble chitosan measured using virus-induced CPE degradation and MTT assay Fig.
Figure 7 illustrates the anti-influenza virus effect of the H3N2 type of propylene glycol (PG) alginate, Na alginate, cross-linked hyaluronic acid (CLHA) and water-soluble chitosan measured using virus-induced CPE degradation and MTT assay Fig.
Figure 8 shows the anti-influenza virus effect of propylene glycol (PG) alginate, Na alginate, cross-linked hyaluronic acid (CLHA) and soluble chitosan against influenza B type using virus-induced CPE degradation and MTT assay Fig.
FIG. 9 is a graph showing changes in body weight after inoculation of 3% dextrose, tamiflu, lambda-carrageenan, and iota-carrageenan twice a day in a white mouse simultaneously with influenza virus.
FIG. 10 is a graph showing the survival rate of influenza virus and 3% dextrose, tamiflu, lambda-carrageenan, and iota-carrageenan in a white mouse by nasally inoculating twice a day.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
실시예Example
실시예Example 1 : One : 카라기난류의Carrageenan 항- term- 리노바이러스Linovirus 효과 확인시험 Effect confirmation test
세포계는 HeLa cell(human cervical carcinoma cell)을 사용하였으며, 약효 검색은 바이러스-유도 CPE(cytopathic effect, CPE) 저해법을 이용하여 카라기난류의 항리노바이러스 효과를 확인하였다. 하기 표 1에 명시된 시험물질을 웰에서의 농도가 500, 167, 56, 19 및 6.2㎍/㎖이 되도록 희석시켜 넣은 다음 인간 리노바이러스 타입 1B(RV1B)를 세포에 감염시켰다. 바이러스를 감염시키고 3일 후에 배양액을 제거하여 살아남은 세포를 MTT(3-(4,5-Dimethylthiazol-2-yl)-2,5 -Diphenyltetrazolim Bromide)로 정량함으로써 항바이러스 효과를 판독하였다(도 1). 람다, 카파, 이오타-카라기난(FMC bioPolymer, USA)은 각각을 증류수에 5㎎/㎖이 되도록 고농축액으로 만든 후 실험 당일 배양액으로 연속 희석하여 사용하였다. 이들 각각의 항-바이러스 효과를 하기의 표 1에 나타내었다.HeLa cell (human cervical carcinoma cell) was used as the cell line and the antitrinin effect of carrageenan was confirmed using the virus - induced CPE (cytopathic effect, CPE) inhibition method. The test substances listed in the following Table 1 were diluted to a concentration of 500, 167, 56, 19 and 6.2 / / ml in the wells, and the cells were infected with human renovirus type 1B (RV1B). Virus was infected and after 3 days, the culture solution was removed and the surviving cells were assayed for antiviral effect by quantifying MTT (3- (4,5-Dimethylthiazol-2-yl) -2,5-diphenyltetrazolim Bromide) . Lambda, Kappa, and Iota-carrageenan (FMC bioPolymer, USA) were each used as a high concentration solution in distilled water at a concentration of 5 mg / ml, and then continuously diluted with the culture medium on the day of the experiment. Each of these anti-viral effects is shown in Table 1 below.
MockCC50 ([mu] g / ml)
Mock
시료 각 농도에서의 % protection(또는 % survival) 값이 높을수록 시료 자체의 독성은 적으면서 항바이러스 효과는 크다고 판단할 수 있다. 바이러스만을 접종하고 시험물질을 첨가하지 않은 바이러스 대조군 웰의 세포 % 생존율은 0% 이며, 시료가 최대의 항바이러스 효과를 나타낸 경우에는 100%로 하였다. 바이러스에 감염된 웰 내의 세포가 50% 생존율을 나타낼 수 있는 약물의 농도를 EC50(50% effective concentration)으로 계산하며, 이 값이 낮을수록 항바이러스 약효가 우수하다고 할 수 있다. 세포 독성은 mock-infected의 결과를 통해 판정하였으며, 약물이 독성을 전혀 나타내지 않을 때는 약물과 바이러스가 첨가되지 않은 대조군 세포와 같이 100% 생존율을 나타낼 것이고, 독성이 강하여 모든 세포를 사멸시킬 경우에는 0% 생존율을 나타낼 것이다. 또한 세포의 50%를 사멸시킬 수 있는 약물의 농도인 CC50(50% cytotoxic concentration)이 높을수록 독성이 적다는 의미가 된다. The higher the% protection (or% survival) value at each sample concentration, the less toxicity of the sample itself and the greater the antiviral effect. The percent cell viability of the virus control wells inoculated with only the virus and the test substance not added was 0%, and was 100% when the sample showed the maximum antiviral effect. The EC 50 (50% effective concentration) is the concentration of the drug capable of showing 50% survival rate in cells infected with the virus. The lower the value, the better the antiviral efficacy. Cytotoxicity was assessed through the mock-infected outcome, and when the drug did not show any toxicity, it would show 100% survival rate as the control cells without added drug and virus, and 0 % Survival rate. Also, the higher the CC 50 (50% cytotoxic concentration), the drug concentration that can kill 50% of the cells, the less toxic it means.
세 가지 카라기난 모두 CC50이 >500㎍/㎖로 독성이 적었으나 그 중에서도 람다-카라기난의 EC50이 <6.2㎍/㎖로 가장 낮아 항-리노바이러스 약효가 가장 뛰어난 것으로 나타났다. All three of the carrageenan CC 50> toxic enemies eoteuna to 500㎍ / ㎖ Among lambda-term to the lowest EC50 is <6.2㎍ / ㎖ of carrageenan - Reno showed the greatest viral drug.
비교예 1: 기타 중합체의 항-리노바이러스 효과 확인Comparative Example 1: Confirmation of anti-lino virus effect of other polymers
하기의 표 2에 명시된 시험물질을 웰에서 최종적으로 500, 167, 56, 19, 6.2㎍/㎖의 농도가 되도록 희석한 다음 실시예 1과 동일하게 실험하여 그 결과를 표 2 및 도 2에 나타내었다.The test substances listed in the following Table 2 were diluted to a final concentration of 500, 167, 56, 19, 6.2 μg / ml in the wells, and then subjected to the same experiment as in Example 1. The results are shown in Table 2 and FIG. 2 .
MockCC 50 ([mu] g / ml)
Mock
카라기난 이외의 중합체를 실험해 본 결과 항-리노바이러스 효과를 나타내는 중합체는 없었다.No polymer other than carrageenan showed any anti-renovirus effect.
실시예 2 : 카라기난류의 항인플루엔자 바이러스 효과 확인Example 2: Confirmation of the effect of carrageenan on the anti-influenza virus
세포계는 MDCK(Madin-Darby, canine kidney) 세포를 사용하였으며, 약효 검색은 바이러스-유도 CPE 저해법을 이용하여 카라기난류의 항인플루엔자바이러스 효과를 확인하였다. 먼저 PR8(인플루엔자A, H1N1), Hong Kong(인플루엔자A, H3N2), Lee(인플루엔자B) 바이러스를 세포에 감염시키고 1시간 후에 바이러스 액을 제거한 다음, 상기 표 1에 명시된 시험물질을 웰에서의 농도가 300.0, 100.0, 33.3, 11.1, 3.7, 1.2, 0.41, 0.14㎍/㎖이 되도록 희석시켜 넣었다. 33℃에서 3일 동안 배양한 다음 MTT 분석을 통해 항바이러스 활성과 세포독성을 측정하였다. The MDCK (Madin-Darby, canine kidney) cell line was used for the cell line, and the anti-influenza virus effect of carrageenan was confirmed using the virus-induced CPE inhibition method. After infecting cells with PR8 (Influenza A, H1N1), Hong Kong (Influenza A, H3N2) and Lee (influenza B) viruses, virus solution was removed after 1 hour, 100.0, 33.3, 11.1, 3.7, 1.2, 0.41, and 0.14 占 퐂 / ml. After incubation at 33 ° C for 3 days, antiviral activity and cytotoxicity were measured by MTT assay.
실시예 2의 결과를 표 3과 H1N1 결과 그래프를 도 3에, H3N2 결과 그래프를 도 4에, 인플루엔자B 결과 그래프를 도 5에 나타내었다. The results of Example 2 are shown in Table 3, the H1N1 result graph is shown in FIG. 3, the H3N2 result graph is shown in FIG. 4, and the influenza B result graph is shown in FIG.
MockCC 50 ([mu] g / ml)
Mock
람다, 카파, 이오타-카라기난 모두 H1N1과 H3N2 타입에 대해 항바이러스 효과를 나타내었고 인플루엔자 B에 대해서는 람다, 이오타-카라기난이 약효를 나타내었다. 그 중에서도 람다-카라기난이 모든 인플루엔자 바이러스 타입들에 대해 가장 큰 약효를 나타내었다. Lambda, kappa, and iota-carrageenan showed antiviral effects against H1N1 and H3N2 types, while lambda and iota-carrageenan showed efficacy against influenza B. Among them, lambda-carrageenan showed the greatest efficacy against all influenza virus types.
비교예 2 : 기타 중합체들의 항인플루엔자 바이러스 효과 확인Comparative Example 2: Identification of anti-influenza virus effect of other polymers
상기 표 2에 명시된 시험물질을 웰에서 최종적으로 300.0, 100.0, 33.3, 11.1, 3.7, 1.2, 0.41, 0.14㎍/㎖의 농도가 되도록 희석한 다음 실시예 2와 동일하게 실험하였다. 결과를 표 4와 H1N1 결과 그래프를 도 6에, H3N2 결과 그래프를 도 7에, 인플루엔자B 결과 그래프를 도 8에 나타내었다.The test substances listed in Table 2 were diluted to a final concentration of 300.0, 100.0, 33.3, 11.1, 3.7, 1.2, 0.41, and 0.14 g / ml in the wells, The results are shown in Table 4, the H1N1 result graph in FIG. 6, the H3N2 result graph in FIG. 7, and the influenza B result graph in FIG.
MockCC 50 ([mu] g / ml)
Mock
모든 중합체들이 세 가지 인플루엔자 바이러스 타입들에 대해 항바이러스 효과를 나타내지 않았다.All polymers did not show antiviral effects against the three influenza virus types.
실시예 3 : 흰마우스에서 람다 카라기난의 항인플루엔자 효과Example 3: Anti-influenza effect of lambda carrageenan in white mice
ICR 마우스에 마우스-적응 PR8 바이러스를 10 x LD50이 되도록 비강 내 접종하였다. 총 50㎕의 3% 덱스트로스에 10LD50의 바이러스 양과 하기 표 5에 명시된 시험물질의 1회 투여 용량을 혼합하여 마우스의 비강을 통해 접종한 후 시험물질들은 전체 부피가 12.5㎕가 되도록 1일 2회씩 투여했으며, 타미플루는 구강을 통해 투여하였다. 바이러스 미감염 대조군(G1)과 감염 대조군(G2)은 3% 덱스트로스만 12.5㎕씩 1일 2회 비강 접종하였고, 매일 오전 같은 시간에 생존 여부를 확인함과 동시에 체중을 측정하여 투여 전 체중에서 30% 이상 체중이 감소하면 안락사 처리하였다.ICR mice were inoculated intranasally with mouse-adapted PR8 virus to 10 x LD50. After a total dose of 10 LD50 of 3% dextrose in a total volume of 50 μl was mixed with a single dose of the test substance listed in Table 5 below, the test materials were inoculated through the nasal passages of the mice, And Tamiflu was administered via the oral cavity. (G1) and the infected control group (G2) were nasally inoculated with 12.5 μl of 3% dextrose twice a day, and their viability was checked at the same time every day at the same time, and the body weight was measured. Euthanasia was treated when the body weight decreased by 30% or more.
(mg/kg/d)Volume
(mg / kg / d)
바이러스 감염 후 2일째부터 G2, G5군은 지속적으로 체중이 감소하여 실험 종료 시점에서 100% 폐사율을 보인 반면, 나머지 군에서는 감염 후 5일 정도까지 체중이 감소되는 경향을 보이다가 점차 회복하여 100% 생존율을 나타내었다. 실시예 3에서의 체중 변화율과 생존율을 표 6과 도 9(체중 변화율), 도 10(생존율)에 각각 나타내었다.From day 2 after viral infection, the G2 and G5 groups continued to lose weight and showed 100% mortality at the end of the experiment. In the remaining group, however, the body weight decreased until 5 days after the infection, Survival rate. The body weight change rate and survival rate in Example 3 are shown in Table 6, FIG. 9 (change in body weight), and FIG. 10 (survival rate), respectively.
* dpi(감염 후 경과일)* dpi (days since infection)
실시예 4 : 카라기난류의 점도시험Example 4: Viscosity test of carrageenan
점도측정은 Brookfield Programmable Digital Viscometer DV-11+ (Brookfield engeneering laboratories, INC., USA)를 이용하여 실시하였으며, USP 37 NF32 (The United States Pharmacopeia, the National Formulary)의 카라기난 시험항목 중 점도(Viscosity) 항에 따라, 각각의 카라기난 1.5% 농도에서 스핀들 1, 30RPM, 75℃에서 측정하였고, 그 결과를 하기 표 7에 나타내었다. Viscosity measurements were performed using a Brookfield Programmable Digital Viscometer DV-11 + (Brookfield engeneering laboratories, INC., USA) and the Viscosity Index of the carrageenan test items of USP 37 NF32 (The United States Pharmacopeia, the National Formulary) , The carrageenan was measured at a concentration of 1.5% at spindle 1, 30 RPM, and 75 캜, and the results are shown in Table 7 below.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (14)
Which comprises as an active ingredient sulfated polysaccharides selected from the group consisting of Lambda-carrageenan, Kappa-carrageenan and Iota-carrageenan, or a pharmaceutically acceptable salt thereof, A composition for preventing or treating rhinovirus or influenza virus infectious diseases.
The composition according to claim 1, wherein the rhinovirus is HRV1B (Human rhinovirus 1B).
2. The composition of claim 1, wherein said influenza virus is selected from the group consisting of H1N1 virus, H3N2 virus and influenza B virus.
The composition of claim 1, wherein the sulfated polysaccharide is lambda-carrageenan.
The composition of claim 4, wherein the lambda-carrageenan has a viscosity of from 100 to 750 mPa · s.
The composition of claim 1, wherein the composition is a composition for nasal administration, wherein the unit dose of the nasal administration is 20 to 500 μg.
The composition of claim 1, wherein the renovirus infectious disease is selected from the group consisting of cold, pneumonia, bronchitis, asthma, chronic obstructive pulmonary disease and cystic fibrosis caused by a rhinovirus infection.
The method according to claim 1, wherein the influenza virus infection disease is selected from the group consisting of bronchitis, rhinitis, sinusitis, croup, acute bronchiolitis, pharyngitis, tonsillitis, laryngitis, tracheitis, asthma and pneumonia caused by influenza virus infection ≪ / RTI >
A functional food composition for improving or alleviating a disease caused by a rhinovirus or an influenza virus infection comprising a sulfated polysaccharide selected from the group consisting of lambda-carrageenan, kappa-carrageenan, and iota-carrageenan as an active ingredient.
10. The composition of claim 9, wherein the renovirus is HRV1B.
10. The composition of claim 9, wherein said influenza virus is selected from the group consisting of H1N1 virus, H3N2 virus and influenza B virus.
10. The composition of claim 9, wherein the sulfated polysaccharide is lambda-carrageenan.
1) 약학적으로 허용되는 담체 및 람다-카라기난, 카파-카라기난 및 이오타-카라기난으로 구성된 군으로부터 선택되는 황산화 다당류 또는 이의 약제학적으로 허용 가능한 염을 정제수에 녹이는 단계; 및
2) 상기 단계 1)에서 얻어진 용액을 무균필터를 포함하는 용기에 충전하는 단계.
A method for preparing a composition for preventing or treating a rhinovirus or influenza virus infection disease comprising the steps of:
1) dissolving a sulfated polysaccharide selected from the group consisting of a pharmaceutically acceptable carrier and lambda-carrageenan, kappa-carrageenan and iota-carrageenan or a pharmaceutically acceptable salt thereof in purified water; And
2) charging the solution obtained in step 1) into a container containing a sterile filter.
1) 약학적으로 허용되는 보존제를 정제수에 녹이는 단계: 및
2) 상기 단계 1)에서 얻어진 용액에 약학적으로 허용되는 담체 및 람다-카라기난, 카파-카라기난 및 이오타-카라기난으로 구성된 군으로부터 선택되는 황산화 다당류 또는 이의 약제학적으로 허용 가능한 염을 추가적으로 녹이는 단계; 및
3) 상기 단계 2)에서 얻어진 용액을 무균필터가 장착 또는 비장착된 용기에 충전하는 단계.A method for preparing a composition for preventing or treating a rhinovirus or influenza virus infection disease comprising the steps of:
1) dissolving a pharmaceutically acceptable preservative in purified water: and
2) additionally dissolving a solution of the sulfated polysaccharide selected from the group consisting of lambda-carrageenan, kappa-carrageenan and iota-carrageenan or a pharmaceutically acceptable salt thereof in the solution obtained in step 1) above; And
3) filling the solution obtained in step 2) into a container with or without sterile filter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180096704A KR101995376B1 (en) | 2018-08-20 | 2018-08-20 | Antiviral Composition Comprising a Carrageenan as an Active Ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180096704A KR101995376B1 (en) | 2018-08-20 | 2018-08-20 | Antiviral Composition Comprising a Carrageenan as an Active Ingredient |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140081882A Division KR20160003964A (en) | 2014-07-01 | 2014-07-01 | Antiviral Composition Comprising a Carrageenan as an Active Ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180096558A true KR20180096558A (en) | 2018-08-29 |
| KR101995376B1 KR101995376B1 (en) | 2019-07-02 |
Family
ID=63434762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180096704A KR101995376B1 (en) | 2018-08-20 | 2018-08-20 | Antiviral Composition Comprising a Carrageenan as an Active Ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101995376B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4079300A1 (en) * | 2021-04-22 | 2022-10-26 | Dutch Renewable Energy B.V. | Anti-viral composition for administration into nose, mouth or throat |
| WO2023031929A1 (en) * | 2021-08-31 | 2023-03-09 | Polyrizon Ltd. | Mucoadhesive polymers for nasal drug delivery |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220008702A (en) | 2020-07-14 | 2022-01-21 | 한미약품 주식회사 | Antiviral composition comprising carrageenan as active ingredient |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5658893A (en) * | 1995-03-29 | 1997-08-19 | Abbott Laboratories | Method for inhibition of rotavirus infection with carrageenan |
| KR20090096598A (en) * | 2006-12-05 | 2009-09-11 | 마리노메드 바이오테크놀로지 게엠베하 | Antiviral composition and method of use |
| KR20100045468A (en) * | 2007-08-24 | 2010-05-03 | 마리노메드 바이오테크놀로지 게엠베하 | Antiviral composition comprising a sulfated polysaccharide |
| JP2013506712A (en) * | 2009-10-06 | 2013-02-28 | ザ・ポピュレイション・カウンシル，インコーポレイテッド | Carrageenan-containing aqueous antibacterial composition |
-
2018
- 2018-08-20 KR KR1020180096704A patent/KR101995376B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5658893A (en) * | 1995-03-29 | 1997-08-19 | Abbott Laboratories | Method for inhibition of rotavirus infection with carrageenan |
| KR20090096598A (en) * | 2006-12-05 | 2009-09-11 | 마리노메드 바이오테크놀로지 게엠베하 | Antiviral composition and method of use |
| KR20100045468A (en) * | 2007-08-24 | 2010-05-03 | 마리노메드 바이오테크놀로지 게엠베하 | Antiviral composition comprising a sulfated polysaccharide |
| JP2013506712A (en) * | 2009-10-06 | 2013-02-28 | ザ・ポピュレイション・カウンシル，インコーポレイテッド | Carrageenan-containing aqueous antibacterial composition |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4079300A1 (en) * | 2021-04-22 | 2022-10-26 | Dutch Renewable Energy B.V. | Anti-viral composition for administration into nose, mouth or throat |
| WO2023031929A1 (en) * | 2021-08-31 | 2023-03-09 | Polyrizon Ltd. | Mucoadhesive polymers for nasal drug delivery |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101995376B1 (en) | 2019-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101995376B1 (en) | Antiviral Composition Comprising a Carrageenan as an Active Ingredient | |
| KR101164515B1 (en) | Composition for Prevention or Treatment of Disease Originated from Influenza Virus | |
| CN106668832B (en) | Application of polypeptide in preparation of medicine for treating enterovirus infection | |
| US11642387B2 (en) | Composition for preventing or inhibiting influenza virus infection, containing ginseng berry polysaccharides | |
| TW202210088A (en) | Pharmaceutical composition and food composition for preventing, alleviating or treating coronavirus infection including elaeocarpus sylvestris extract as active ingredient | |
| US8470378B2 (en) | Anti-influenza viral composition containing bark or stem extract of Alnus japonica | |
| KR20160003964A (en) | Antiviral Composition Comprising a Carrageenan as an Active Ingredient | |
| KR20160112836A (en) | Composition for enhancing innate immunity and antivirus comprising Pini Pollen extract as effective component | |
| KR101951003B1 (en) | Composition for enhancing innate immunity and antivirus comprising Echinopsis Radix extract as effective component | |
| KR101951010B1 (en) | Composition for enhancing innate immunity and antivirus comprising Isatidis Folium extract as effective component | |
| KR101874465B1 (en) | Composition for enhancing innate immunity and antivirus comprising Eupatorii Herba extract as effective component | |
| KR20170030689A (en) | Aloe composition for influenza vaccine adjuvants and influenzq vaccine composition comprising the same | |
| KR101782847B1 (en) | Composition for enhancing innate immunity and antivirus comprising Hoveniae Semen Cum Fructus extract as effective component | |
| CN100463680C (en) | Composition comprising soluble glucan oligomer from saccharomyces cerevisiae IS2 inhibiting the swine influenza (SIV) and transmissible gastroenteritis coronavirus (TGEV) | |
| KR101334348B1 (en) | Flavonoid Comprising Anti-Virus Activity | |
| KR101837445B1 (en) | Composition for enhancing innate immunity and antivirus comprising Dianthi Herba extract as effective component | |
| KR101770572B1 (en) | Composition for enhancing innate immunity and antivirus comprising Mori Ramulus or Mori Radicis Cortex extract as effective component | |
| KR101837448B1 (en) | Composition for enhancing innate immunity and antivirus comprising Piperis Longi Fructus extract as effective component | |
| CN105434631A (en) | Application of zanthoxylum oil in preparing drugs or health-care products for preventing and/or treating virus flu | |
| RU2780346C1 (en) | Therapeutic agent against coronavirus including an elaeocarpus sylvestris extract | |
| KR20160115374A (en) | Composition for enhancing innate immunity and antivirus comprising Hoveniae Semen Cum Fructus extract as effective component | |
| KR20160115379A (en) | Composition for enhancing innate immunity and antivirus comprising Psoraleae Semen extract as effective component | |
| JP2011088881A (en) | Anti-influenza viral agent and food and drink or drug including the same substance | |
| WO2012139521A1 (en) | Traditional chinese medicinal composition for preventing and treating influenza a and preparation method therefor and use thereof | |
| CN113491668B (en) | Pharmaceutical composition preparation for injection and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |